What do systematic reviews say?

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 1996 participants
  Low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 1433 participants
  Moderate
• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  25 studies · 2129 participants
  Moderate

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 235 participants
  Low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 816 participants
  Very low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 1289 participants
  Low
• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  26 studies · 2020 participants
  Moderate

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 863 participants
  Very low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  26 studies · 2102 participants
  Moderate

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 326 participants
  Very low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 657 participants
  Low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 1265 participants
  Moderate

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 1459 participants
  Low

Physical activity vs control

• Physical activity for women with breast cancer after adjuvant therapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 1579 participants
  Low

Boost vs no boost

Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 0.64 [0.55, 0.75]
  5 studies · 8315 participants
  Low

Boost vs no boost

Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 1.04 [0.94, 1.14]
  2 studies · 6342 participants
  Moderate

Boost vs no boost

Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 0.94 [0.87, 1.02]
  3 studies · 6549 participants
  Low

Boost vs no boost

It is very uncertain whether boost changes late toxicity, pBRA compared with no boost (very low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  MD 0.38
  2 studies · 1526 participants
  Very low

Boost vs no boost

Boost may leads to higher cosmesis, panel scored: fair or poor compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  OR 1.41 [1.07, 1.85]
  2 studies · 1116 participants
  Low
• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  OR 1.58 [0.93, 2.69]
  2 studies · 592 participants
  Very low